Concepedia

Chudi Ndubaku

CN

Statistics

Publications

27

Citations

2.9K

H-Index

23

Active since

2002

Affiliations

Aduro BioTech (United States)(Current)

University of California, Berkeley

Genomics Institute of the Novartis Research Foundation

University of Pennsylvania

Walter and Eliza Hall Institute of Medical Research

Chudi Ndubaku is an author at Aduro BioTech (United States) specializing in medicinal chemistry, drug discovery, and pharmacology.

ORCID

Publications per year

2002–2022

27

Publications

27

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity

Kelsey E. Sivick, Anthony L. Desbien, Laura Hix Glickman et al. · Cell Reports · 2018 · 438 citations · Full text

, , +17

USP7 small-molecule inhibitors interfere with ubiquitin binding

Lorna Kategaya, Paola Di Lello, Lionel Rougé et al. · Nature · 2017 · 346 citations · Full text

, , +13

Discovery of a Potent and Selective BCL-X <sub>L</sub> Inhibitor with <i>in Vivo</i> Activity

Zhi‐Fu Tao, Lisa Hasvold, Le Wang et al. · ACS Medicinal Chemistry Letters · 2014 · 331 citations · Full text

, , +10

NK cells mediate clearance of CD8 <sup>+</sup> T cell–resistant tumors in response to STING agonists

Christopher J. Nicolai, Natalie K. Wolf, I-Chang Chang et al. · Science Immunology · 2020 · 266 citations · Full text

, , +17

Discovery of 2-{3-[2-(1-Isopropyl-3-methyl-1<i>H</i>-1,2–4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-<i>d</i>][1,4]oxazepin-9-yl]-1<i>H</i>-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): A β-Sparing Phosphoinositide 3-Kinase Inhibitor with High Unbound Exposure and Robust in Vivo Antitumor Activity

Chudi Ndubaku, Timothy P. Heffron, Steven T. Staben et al. · Journal of Medicinal Chemistry · 2013 · 176 citations · Full text

, , +13

1–5 of 27